Western Blot: Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.
Immunohistochemistry-Paraffin: Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody ...read more
Flow (Cell Surface): Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a ...read more
Flow Cytometry: Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC
Flow (Cell Surface): Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and ...read more
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Buffer
PBS
Preservative
0.02% Sodium Azide
Concentration
1.0 mg/ml
Purity
IgM purified
Notes
CLA antibody clone HECA-452 is known to recognize the cutaneous lymphocyte-associated antigen / CLA which is a specialized glycosylated form of P-selectin glycoprotein ligand-1/PSGL-1. Besides lymphocytes, this clone has been shown to react with normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).
Alternate Names for PSGL-1/CD162 Antibody (HECA-452)
Cutaneous Lymphocyte Antigen (CLA) is a single-pass type I membrane homodimer protein (140kDa) that collects in normal and inflamed skin. It is expressed on T lymphocytes, subsets of peripheral blood memory T cells, Natural Killer cells, memory B cells and dendritic cells, as well as on monocytes and granulocytes. CLA is a carbohydrate epitope of sialic acid and fucose-modified P-selectin glycoprotein ligand-1 (PSGL-1). CLA is a subset ligand for E-selectin, P-selectin, and L-selectin. It plays a role in leukocyte tethering and rolling over vascular surfaces during inflammation. Treatment of activated HUVEC cells with HECA-452 antibody inhibits lymphocyte adhesion. The HECA-452 antibody is cross-reactive with mouse CLA and is appropriate for staining formalin-fixed paraffin embedded tissue sections.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Bioinformatics Tool for PSGL-1/CD162 Antibody (NB100-78039)
Discover related pathways, diseases and genes to PSGL-1/CD162 Antibody (NB100-78039). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for PSGL-1/CD162 Antibody (NB100-78039)
Discover more about diseases related to PSGL-1/CD162 Antibody (NB100-78039).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our PSGL-1/CD162 Antibody (HECA-452) and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.